Brought to you by 
ZymoGenetics spins off of Novo Nordisk; raises $150mm
24 Jun 2020
Executive Summary
Novo Nordisk AS has spun-off its US subsidiary ZymoGenetics through the sale of $150mm worth of the unit's stock, a 35% stake, to a group of investors led by EM Warburg, Pincus & Co.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ZymoGenetics spins off of Novo Nordisk; raises $150mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice